Estudo mostra risco aumentado de síndrome de Guillain-Barré após vacina da J&J; a razão de taxas foi de 4,18 para uma janela de 42 dias.
8 Out, 2021 | 12:27h
Comentário no Twitter
Study suggests a potential small but statistically significant safety concern for #GuillainBarré syndrome following receipt of the @JanssenUS #COVID19 vaccine; findings considered preliminary pending analysis of medical records to establish a definitive Dx https://t.co/yZjJVkp6BA
— JAMA (@JAMA_current) October 7, 2021